ClinicalTrials.gg
CompletedNCT05763823Updated Mar 25, 2025Results posted

A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

A Phase 3 interventional study of Letermovir in Cytomegalovirus Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Enrollment
4th of 17
120 · median 80
Started
2023
with 3 others
Phase 3
6 of 17
3 open now
Registered
8th of 17
by date
Lead sponsor
4 of 17
Merck Sharp & Dohme LLC

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 4th largest by enrollment, is one of 4 that started in 2023, is one of 6 in phase 3, and was the 8th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (IV) dose of Letermovir (MK-8228) in Chinese adult hematopoietic stem cell transplant (HSCT) recipients for the prevention of clinically significant cytomegalovirus (CMV) infection.

03

Conditions studied

  • Cytomegalovirus Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Male/Female Chinese adult participant of an Hematopoietic Stem Cell Transplant (HSCT).
  • Has documented positive Cytomegalovirus (CMV) serostatus (CMV immunoglobulin G [IgG] seropositive) for recipient (R+) at the time of screening.
  • Is receiving a first allogeneic HSCT.
  • Is within 28 days post-HSCT at the time of randomization.
  • Female participant is not a Woman of Child Bearing Potential () or is a WOBCP who agrees to use acceptable during the treatment period and for ≥28 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Received a previous HSCT.
  • Has a history of CMV end-organ disease within 6 months prior to randomization.
  • Has evidence of CMV viremia at any time from HSCT procedure until the time of randomization.
  • Has severe hepatic insufficiency.
  • Is a) on renal replacement therapy (e.g., hemodialysis, peritoneal dialysis) OR b) has end stage renal impairment with a \<=10 mL/min within 5 days prior to randomization.
  • Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency.
  • Has an uncontrolled infection on the day of randomization.
  • Has rapidly progressing disease that requires mechanical ventilation or is hemodynamically unstable.
  • Has a documented positive result for a antibody (HIV-Ab) test at any time prior to randomization, or for virus antibody (HCV-Ab) with detectable HCV ribonucleic acid (RNA), or surface antigen (HBsAg) within 90 days prior to randomization.
  • Has active solid tumor except localized basal cell or squamous cell skin cancer or the condition under treatment (e.g., lymphomas).
  • Has received any prohibited medications within 2 days prior to initiation of treatment with Letermovir.
  • Is anticipated to be treated with Traditional Chinese Medicine or herbal medicine during the study treatment period and for 14 days after study medication.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Letermovir

    Chinese HSCT recipients will receive 240 mg of Letermovir \[for participants on Cyclosporin A (CsA)\] or 480 mg of Letermovir (for participants not on CsA) either orally or IV once daily through week 14 (\~100 days) post-transplant.

    Drug: Letermovir

Interventions

  • Daily 240 mg or 480 mg oral tablets or IV dose

    Also known as: MK-8228

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant

    Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to week 24 post-transplant is reported.

    Time frame: Up to Week 24 post-transplant (approximately 6 months)

Secondary outcomes

  1. Percentage of Participants Who Experienced an Adverse Event (AE)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.

    Time frame: Up to 16 weeks

  2. Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.

    Time frame: Up to 14 weeks

  3. Percentage of Participants With Clinically Significant CMV Infection up to Week 14 Post-Transplant

    Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to 14 weeks post-transplant is reported.

    Time frame: Up to 14 weeks post-transplant (99 days)

  4. Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 14 Post-Transplant

    Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 14 weeks post-transplant is reported.

    Time frame: Up to 14 weeks post-transplant (99 days)

  5. Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 24 Post-Transplant

    Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 24 weeks post-transplant is reported.

    Time frame: Up to 24 weeks post-transplant (approximately 6 months)

  6. Percentage of Participants With CMV End-organ Disease up to Week 14 Post-Transplant

    CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 14 weeks post-transplant is reported.

    Time frame: Up to 14 weeks post-transplant (99 days)

  7. Percentage of Participants With CMV End-organ Disease up to Week 24 Post-Transplant

    CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 24 weeks post-transplant is reported.

    Time frame: Up to 24 weeks post-transplant (approximately 6 months)

  8. Percentage of Participants With All-Cause Mortality up to Week 14 Post-Transplant

    The percentage of participants who died due to any cause up to 14 weeks post-transplant is reported.

    Time frame: Up to 14 weeks post-transplant (99 days)

  9. Percentage of Participants With All-cause Mortality up to Week 24 Post-Transplant

    The percentage of participants who died due to any cause up to 24 weeks post-transplant is reported.

    Time frame: Up to 24 weeks post-transplant (approximately 6 months)

07

Results

Posted Mar 25, 2025

Participant flow

Participant flow — Overall Study
MilestoneLetermovir
Started120
Completed107
Not completed13
Withdrew: Death6
Withdrew: Withdrawal by parent/guardian1
Withdrew: Withdrawal by subject6

Outcome measures

PrimaryPercentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant

Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to week 24 post-transplant is reported.

Time frame:
Up to Week 24 post-transplant (approximately 6 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant32 (23.5 to 42.9)
SecondaryPercentage of Participants Who Experienced an Adverse Event (AE)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.

Time frame:
Up to 16 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of ParticipantsLetermovir
Percentage of Participants Who Experienced an Adverse Event (AE)99.2 (95.4 to 100.0)
SecondaryPercentage of Participants Who Discontinue Study Treatment Due to an Adverse Event

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.

Time frame:
Up to 14 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event
Percentage of ParticipantsLetermovir
Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event0 (NA to NA)
SecondaryPercentage of Participants With Clinically Significant CMV Infection up to Week 14 Post-Transplant

Clinically significant CMV infection was defined as either one of the following: 1) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant or 2) onset of CMV end-organ disease. The percentage of participants with clinically significant CMV infection up to 14 weeks post-transplant is reported.

Time frame:
Up to 14 weeks post-transplant (99 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinically Significant CMV Infection up to Week 14 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With Clinically Significant CMV Infection up to Week 14 Post-Transplant7.1 (2.9 to 14.2)
SecondaryPercentage of Participants With Preemptive Therapy for CMV Viremia up to Week 14 Post-Transplant

Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 14 weeks post-transplant is reported.

Time frame:
Up to 14 weeks post-transplant (99 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 14 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 14 Post-Transplant7.1 (2.9 to 14.2)
SecondaryPercentage of Participants With Preemptive Therapy for CMV Viremia up to Week 24 Post-Transplant

Initiation of anti-CMV preemptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV preemptive anti-CMV therapy up to 24 weeks post-transplant is reported.

Time frame:
Up to 24 weeks post-transplant (approximately 6 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 24 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With Preemptive Therapy for CMV Viremia up to Week 24 Post-Transplant32.7 (23.5 to 42.9)
SecondaryPercentage of Participants With CMV End-organ Disease up to Week 14 Post-Transplant

CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 14 weeks post-transplant is reported.

Time frame:
Up to 14 weeks post-transplant (99 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With CMV End-organ Disease up to Week 14 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With CMV End-organ Disease up to Week 14 Post-Transplant6.1 (2.3 to 12.9)
SecondaryPercentage of Participants With CMV End-organ Disease up to Week 24 Post-Transplant

CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease will be included in this analysis. The percentage of participants with CMV end-organ disease up to 24 weeks post-transplant is reported.

Time frame:
Up to 24 weeks post-transplant (approximately 6 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With CMV End-organ Disease up to Week 24 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With CMV End-organ Disease up to Week 24 Post-Transplant11.2 (5.7 to 19.2)
SecondaryPercentage of Participants With All-Cause Mortality up to Week 14 Post-Transplant

The percentage of participants who died due to any cause up to 14 weeks post-transplant is reported.

Time frame:
Up to 14 weeks post-transplant (99 days)
Reported as:
Number · Percentage of Participants
Percentage of Participants With All-Cause Mortality up to Week 14 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With All-Cause Mortality up to Week 14 Post-Transplant5.1 (1.7 to 11.5)
SecondaryPercentage of Participants With All-cause Mortality up to Week 24 Post-Transplant

The percentage of participants who died due to any cause up to 24 weeks post-transplant is reported.

Time frame:
Up to 24 weeks post-transplant (approximately 6 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With All-cause Mortality up to Week 24 Post-Transplant
Percentage of ParticipantsLetermovir
Percentage of Participants With All-cause Mortality up to Week 24 Post-Transplant6.1 (2.3 to 12.9)

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letermovir8/120 (6.7%)70/120 (58.3%)118/120 (98.3%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventLetermovir
PneumoniaInfections and infestations17/120
Acute graft versus host diseaseImmune system disorders14/120
Cystitis haemorrhagicRenal and urinary disorders12/120
Epstein-Barr virus infectionInfections and infestations8/120
Cytomegalovirus infectionInfections and infestations7/120
Epstein-Barr viraemiaInfections and infestations6/120
ThrombocytopeniaBlood and lymphatic system disorders4/120
Acute graft versus host disease in intestineImmune system disorders4/120
Cytomegalovirus viraemiaInfections and infestations4/120
AnaemiaBlood and lymphatic system disorders3/120
Most frequent other events
Showing 10 of 53
Most frequent other events
EventLetermovir
HypokalaemiaMetabolism and nutrition disorders39/120
VomitingGastrointestinal disorders37/120
PyrexiaGeneral disorders32/120
NauseaGastrointestinal disorders27/120
White blood cell count decreasedInvestigations27/120
RashSkin and subcutaneous tissue disorders26/120
DiarrhoeaGastrointestinal disorders25/120
Epstein-Barr virus infectionInfections and infestations20/120
Platelet count decreasedInvestigations20/120
HyponatraemiaMetabolism and nutrition disorders20/120

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Letermovir
Mean37.8 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Letermovir
Female45
Male75
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Letermovir
Hispanic or Latino0
Not Hispanic or Latino120
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Letermovir
American Indian or Alaska Native0
Asian120
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

21 sites
  • Anhui Provincial Hospital ( Site 0024)
    Hefei, Anhui 230071, China
  • Peking University First Hospital ( Site 0009)
    Beijing, Beijing 100034, China
  • Peking University People's Hospital-Hematology ( Site 0033)
    Beijing, Beijing 100034, China
  • The Second Affiliated Hospital of Third Military Medical University-Oncology Department ( Site 0002)
    Chongqing, Chongqing 400037, China
  • Southwest Hospital of Third Military Medical University ( Site 0005)
    Chongqing, Chongqing 400038, China
  • The Second Affiliated Hospital Chongqing Medical University ( Site 0013)
    Chongqing, Chongqing 400072, China
  • Guangzhou First People's Hospital-Hematology Department ( Site 0001)
    Guangzhou, Guangdong 510180, China
  • Southern Medical University Nanfang Hospital ( Site 0003)
    Guangzhou, Guangdong 510515, China
  • Shenzhen Second People's Hospital-Hematology Department ( Site 0006)
    Shenzhen, Guangdong 518035, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0028)
    Wuhan, Hubei 430022, China
  • Tongji Hospital Tongji Medical,Science & Technology ( Site 0032)
    Wuhan, Hubei 430030, China
  • The First Affiliated Hospital of Soochow University-hematology department ( Site 0029)
    Suzhou, Jiangsu 215006, China
  • The Affiliated Hospital of Xuzhou Medical College ( Site 0022)
    Xuzhou, Jiangsu 221006, China
  • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0021)
    Nanchang, Jiangxi 330209, China
  • The First Hospital of Jilin University-Hematology ( Site 0023)
    Changchun, Jilin 130021, China
  • The 2nd Affiliated Hospital of Dalian Medical University ( Site 0019)
    Dalian, Liaoning 116023, China
  • Shanghai General Hospital ( Site 0018)
    Shanghai, Shanghai 200080, China
  • West China Hospital, Sichuan University ( Site 0008)
    Chengdu, Sichuan 610041, China
  • The General Hospital of Western Theater Command ( Site 0007)
    Chengdu, Sichuan 610083, China
  • Institute of hematology&blood disease hospital-Hematology ( Site 0030)
    Tianjin, Tianjin 300020, China
  • The First Affiliated Hospital, Zhejiang University ( Site 0025)
    Hangzhou, Zhejiang 310003, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Apr 2024, 12 months.

Results were first posted in Mar 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Mar 10, 2023
StartActual
Mar 24, 2023
Primary completionActual
Apr 18, 2024
CompletionActual
Apr 18, 2024
Results first posted
Mar 25, 2025
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05763823
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Mar 24, 2023
Primary completion
Apr 18, 2024
Completion
Apr 18, 2024
Results posted
Mar 25, 2025
Last update
Mar 25, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion